Appetite & satiety signaling
One of 6 mechanistic pathways to 🔥 Lose fat · 25 options
Incretin and amylin receptors in the hypothalamus and brainstem set how much food it takes to feel done, and how fast the stomach empties. Engage them and intake falls without willpower being involved. This is the most clinically developed pathway in the whole Vault — and the least interesting one if your intake is already low.
High fasting insulin with a normal glucose is the classic pre-diabetic picture, and it means appetite is being driven hormonally rather than by willpower. That is the strongest argument for this pathway. If insulin is genuinely low and you still can't stop eating, the driver is behavioral or psychological and no incretin will fix it.
Fasting InsulinHbA1c (Hemoglobin A1c)C-Peptide, Serum📉 Insulin Resistance Deep Dive covers these in one panel →
What engages this pathway
Ordered by how directly each one acts on the mechanism above — never by how much trial evidence exists. Each links to its full breakdown with dosing, half-life and vendor.
🧬 African Mango
The trial results are the story. The original seed-extract studies report leptin down 48% and adiponectin up 160% over ten weeks, effect sizes that imply a daily deficit no one in the study was told to run. An independent group at the same dose found essentially nothing. The plausible mechanism — soluble fiber — has its own literature, and it pools to about a kilogram.
🧬 Green Coffee Bean Extract
Chlorogenic acids, and the honest headline is that the 2012 trial which built the category was retracted and the sponsor settled with the FTC. Mechanistically the molecule barely gets a chance: gut microbiota hydrolyze it before absorption, so what circulates is caffeic and ferulic acid, not the intact ester the enzyme work was done on.
💉 Retatrutide
Triple GLP-1/GIP/glucagon agonism — the glucagon arm adds hepatic fat oxidation and energy expenditure on top of appetite suppression, which is why its phase-2 numbers outrun the duals. The only one here arguing on two pathways at once.
💉 UBT251
The same GLP-1/GIP/glucagon triple design as Retatrutide, from a different developer. If the class argument holds — the glucagon arm adding expenditure on top of appetite suppression — this should behave like the molecule above it; the published human data behind it is a fraction of Retatrutide's, so that is a class expectation rather than a result.
💉 Tirzepatide
Dual GIP/GLP-1. GIP appears to improve the tolerability ceiling, so more people reach a dose that actually suppresses intake rather than quitting at nausea.
💉 Semaglutide
The reference GLP-1. Slows gastric emptying and raises satiety centrally; the fat loss is almost entirely downstream of eating less.
💉 Survodutide
GLP-1/glucagon dual. Same theoretical advantage as retatrutide's glucagon arm — expenditure plus appetite — without the GIP component.
💉 Mazdutide
GLP-1/glucagon dual developed largely in Chinese trials; mechanistically parallel to survodutide.
💉 Pemvidutide
GLP-1/glucagon tuned deliberately toward liver-fat reduction and lean-mass preservation rather than maximum scale weight loss.
💉 Orforglipron
Oral non-peptide GLP-1 — the mechanism is unchanged, the delivery is the innovation. Matters if needles are your adherence problem.
💉 Ecnoglutide
Long-acting GLP-1 analog engineered for weekly dosing with a cAMP-biased signaling profile.
💉 Amycretin
Single molecule hitting both GLP-1 and amylin receptors. Early human data looks strong, but it is early — the trial base is thin next to the duals.
💉 Cagrilintide
Long-acting amylin analog. Amylin slows gastric emptying and signals satiety through a route GLP-1 doesn't use, which is the argument for stacking it rather than replacing.
💉 Eloralintide
Selective amylin-receptor agonist. The selectivity argument is that you get satiety with less of the nausea that comes from broad calcitonin-family activity — plausible, and not yet settled in humans.
💉 Pramlintide
The original amylin analog, approved alongside insulin. Proof the amylin pathway moves intake in humans; short half-life makes it fiddly.
💉 Liraglutide
Daily GLP-1. Superseded on convenience, not on mechanism.
💉 Dulaglutide
Weekly GLP-1 built for glycemic control; weight loss is real but a smaller effect than the newer agents.
💉 Exenatide
The first-generation GLP-1, derived from Gila monster venom. Historically important, mechanistically identical, clinically outclassed.
💉 Metatrutide
Marketed as a triple-agonist analog. Treat the identity and purity as the open question here, not the pathway.
💉 Tesofensine
Triple monoamine reuptake inhibition — dopamine, noradrenaline, serotonin. Appetite suppression via a completely different route to the incretins, with the blood-pressure and mood consequences you'd predict from that mechanism.
💉 Ondansetron
A 5-HT3 antagonist used for nausea. The extrapolation: it makes GLP-1 titration tolerable, which indirectly makes fat loss possible. It is not a fat-loss agent itself.
🧬 Glucomannan
Konjac fiber that gels in the stomach — mechanical satiety with no receptor pharmacology at all. The cheapest version of this pathway.
🧬 Psyllium Husk
Viscous soluble fiber. Slows gastric emptying and blunts the post-meal glucose curve; modest, real, and it stacks with everything.
🧬 Gymnema Sylvestre
Gymnemic acids transiently block sweet-taste receptors on the tongue and possibly in the gut. The prediction is reduced sweet-seeking rather than reduced total intake.
🧬 GLP-1 Support Stack
Formulated around the side-effect profile of GLP-1 use — constipation, muscle loss, micronutrient gaps. Supportive, not causal.
What actually decides this outcome, in order of size
These are prescription-grade receptor agonists and the honest ranking puts three clinical questions above every molecule on the list. Ranked by how much of the outcome each one owns:
- Whether the difficulty is the satiety signal at all. These drugs act on receptors that set meal termination and gastric emptying Drucker 2022. They do that whether or not the signal was the reader's problem. Somebody whose intake is already modest, or whose relationship with food is the difficulty rather than its volume, is outside what this pharmacology addresses and is looking at the wrong page.
- Who is prescribing and who is monitoring. This is not a supplement shelf. It is a class with defined contraindications, a pancreatitis and gallbladder signal, thyroid C-cell labeling for several agents, and anesthetic implications from delayed gastric emptying. Every trial cited on this page was run with clinical oversight, and the oversight is part of the intervention rather than a formality around it.
- What the outcome data actually attaches to, which is not the scale. In SELECT, cardiovascular outcomes with semaglutide were examined by baseline glycated hemoglobin and by change in it Lingvay 2024. The benefit did not turn out to be a story about glycemic improvement, which is a strong hint that the mechanism is broader than the weight or the sugar.
- Body composition, because the loss is not all adipose. Bimagrumab was tested with and against semaglutide specifically because lean mass is part of what comes off Heymsfield 2026. That is the trade this class makes, it is measurable, and it is the reason resistance training belongs beside the prescription rather than after it.
- The molecules, last, and they are not interchangeable. A triple agonist at GIP, GLP-1 and glucagon receptors is a different pharmacology from a selective amylin receptor agonist Jastreboff 2023 Billings 2025, an oral small-molecule GLP-1 agonist is a different exposure profile again Horn 2025, and combinations behave differently from either component Garvey 2025.
The order to run these in, and what has to be true first
Clinical assessment, then baseline bloods, then one agent, then monitoring on a schedule. Nothing on this page is a self-directed purchase and the order below assumes a prescriber.
- A clinical conversation before a molecule, including the questions this page cannot ask. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, pancreatitis, gallstones, gastroparesis, pregnancy or planned pregnancy, and current medications. Any one of these changes the answer.
- Baseline bloods, on one requisition. HbA1c (Hemoglobin A1c) with the Comprehensive Metabolic Panel (CMP), Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) with ApoB (Apolipoprotein B), and Amylase with Lipase so that a later abdominal pain has something to be compared against. Calcitonin is not a screening test for this indication and should not be ordered as one.
- Semaglutide or Tirzepatide first among the injectables, because they carry the largest randomized outcome files. The SELECT analysis is the strongest single reason to prefer an agent with hard endpoints over one with only weight data Lingvay 2024.
- Orforglipron and Ecnoglutide are the oral and biased-agonist end of the same receptor. An oral small-molecule GLP-1 agonist has phase 3 data Horn 2025, and the practical difference from an injectable is exposure profile and administration rather than mechanism.
- Retatrutide, Survodutide, Mazdutide, Pemvidutide and Metatrutide add glucagon or GIP receptor activity. Retatrutide's phase 2 results are published Jastreboff 2023 and later data has followed Bajaj 2026; a glucagon component raises energy expenditure and also raises the monitoring burden.
- Cagrilintide, Eloralintide, Pramlintide and Amycretin are the amylin arm and it is a different receptor family. Amylin's mediators in metabolic control have been reviewed Boyle 2022, chronic pramlintide reduced feeding via a reduction in meal size in a preclinical model Kern 2024, and a selective amylin receptor agonist has phase 1 data Billings 2025. Combination with a GLP-1 agonist has its own randomized evidence Garvey 2025.
- Resistance training alongside, from week one rather than after the weight has gone. The lean-mass question is the one the bimagrumab work exists to address Heymsfield 2026, and the free version of that intervention is loading the muscle while the energy deficit is happening.
- Glucomannan, Psyllium Husk, Gymnema Sylvestre, Tesofensine and Ondansetron are a different page pretending to be on this one. The first two are viscous fibers acting on gastric volume, the third is a botanical, and the last two are a monoamine reuptake inhibitor and an antiemetic. None of them is an incretin, and the pooled effect of the fiber arm is not in the same units as the pharmacology above it.
What gets bought for this that cannot move it
The category that fails structurally is the fiber and botanical arm sold on the same page as the pharmacology. A viscous fiber increases gastric volume and slows transit mechanically; an incretin agonist engages a receptor system that sets meal termination centrally and peripherally Drucker 2022. Both reduce intake and the effect sizes are not remotely comparable. Putting them in one list invites a reader to substitute the cheap one for the expensive one and conclude the mechanism does not work.
The lean-mass cost is the part of this class most often left out. Weight lost under any energy deficit includes muscle, and the specific reason a myostatin-pathway antibody was combined with semaglutide in a trial is that this is a known and measurable problem Heymsfield 2026. It is not a reason to avoid the class. It is a reason to measure body composition rather than body mass, and to train throughout.
And the reader this page is most likely to harm is the one whose intake is already low. Suppressing an appetite signal that is already suppressed produces no useful weight change and a real risk of inadequate nutrition. If food is a source of distress rather than a quantity problem, if eating is already restricted, or if the relationship with eating is what actually needs attention, this pharmacology is the wrong instrument and the right step is a clinician who works with eating rather than a prescription that reduces it. That is not a hedge; it is the honest boundary of what this page covers.
If the goal underneath is different, so is the page. Protecting muscle during a deficit is Lean-mass protection while cutting. A resting metabolic rate that has fallen is Thyroid & thermogenic substrate. Insulin sensitivity as the actual target is Metabolic health & insulin sensitivity. And severe or persistent abdominal pain on any agent in this class is an urgent assessment, not a dose adjustment.
How you would know it was working, on a real read-out and a real timescale
This page makes two predictions. Waist circumference and HbA1c (Hemoglobin A1c) should both move within twelve weeks on an effective agent at an effective exposure; and if body mass falls while a strength measure falls with it, the loss is not the composition the reader wanted. The second prediction is the one nobody checks.
- Waist circumference and body mass weekly, same conditions, plus one strength measure. Grip dynamometry or a fixed five-repetition load. The strength number is what turns a weight trend into a body composition statement without a scan, and it is the read-out the lean-mass literature implies Heymsfield 2026.
- HbA1c (Hemoglobin A1c) at baseline and 12 weeks. Twelve weeks because glycated hemoglobin integrates over the circulating red cell population. Note that the SELECT analysis found the cardiovascular benefit was not explained by where this number started or how far it moved Lingvay 2024, so a flat HbA1c is not evidence the drug is failing.
- Amylase and Lipase at baseline, and only repeated if abdominal pain appears. They exist here as a comparison value. Ordering them monthly in an asymptomatic person generates false alarms rather than safety.
- Comprehensive Metabolic Panel (CMP) and Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) with ApoB (Apolipoprotein B) at baseline and at 6 months. Renal function matters if vomiting or diarrhea occurs, and apolipoprotein B is the lipid read-out that survives a large change in weight better than cholesterol mass does.
- Ferritin, Vitamin B12 and Vitamin D (25-Hydroxy) once at six months. Sustained reduced intake reduces micronutrient intake too, and these three are the ones that become symptomatic first.
What will fool you. The first fortnight on any of these agents includes fluid and gastrointestinal content, so early weight change overstates fat loss. Nausea suppresses intake independently of the satiety mechanism, which means a tolerability problem can look like efficacy Drucker 2022. Waist circumference measured at a different landmark is a different number, so mark the site. Amylin and incretin agents both delay gastric emptying Boyle 2022, which changes the absorption of anything taken with them and matters for oral contraceptives and for drugs with narrow windows. And an unlicensed vial of any of these has no assay behind it: the dose written on it is a claim.
Sources read for these sections
- Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism 2022 · PMID 34626851
- Lingvay I. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT. Diabetes Care 2024 · PMID 38907684
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. New England Journal of Medicine 2023 · PMID 37366315
- Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2025 · PMID 40544433
- Dahl K, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. The Lancet 2025 · PMID 40550231
- Horn DB, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. The Lancet 2025 · PMID 41275875
- Boyle CN, Le Foll C, Lutz TA. Mediators of Amylin Action in Metabolic Control. Journal of Clinical Medicine 2022 · PMID 35456307
- Heymsfield SB, et al. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. Nature Medicine 2026 · PMID 41772149
- Kern KA, et al. Chronic pramlintide decreases feeding via a reduction in meal size in male rats. Peptides 2024 · PMID 38493922
- Billings LK, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2025 · PMID 41207310
- Bajaj HS, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet 2026 · PMID 42250575
The other 5 routes to lose fat
Pick the pathway that matches where you are actually stuck. An appetite drug does nothing for someone who already undereats.
You know the goal. Skool has the plan.
This pathway is one arm of The Lose fat Blueprint. The members' version has where this arm sits in the sequence, what to stack it with, and the markers that tell you to keep going or stop.
Open The Lose fat Blueprint in Skool →$10/mo, cancel anytime.
← Open this pathway in the interactive Vault
Frequently asked questions
Incretin and amylin receptors in the hypothalamus and brainstem set how much food it takes to feel done, and how fast the stomach empties. Engage them and intake falls without willpower being involved. This is the most clinically developed pathway in the whole Vault — and the least interesting one if your intake is already low.
25 options are mapped to this pathway in the Vault, including African Mango, Green Coffee Bean Extract, Retatrutide, UBT251. They are grouped by the mechanism they act through rather than ranked by how much trial evidence exists — 16 carry clinical validation and 9 are mechanistic predictions.
High fasting insulin with a normal glucose is the classic pre-diabetic picture, and it means appetite is being driven hormonally rather than by willpower. That is the strongest argument for this pathway. If insulin is genuinely low and you still can't stop eating, the driver is behavioral or psychological and no incretin will fix it. The markers worth checking are Fasting Insulin, HbA1c (Hemoglobin A1c), C-Peptide, Serum.
Unproven is not the same as ineffective. Of the 25 options on this pathway, 16 have clinical validation and 9 are graded theoretical — meaning the mechanism is sound but the specific human trial has not been run, which is true of a great deal of what works in this space. Nothing on this page is ordered by evidence tier, because sorting by trial count would bury the compounds you came looking for.
Where this goes next
Everything above is the free case for Appetite & satiety signaling. The protocol — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.